Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints

[1]  R. Sampogna,et al.  Disaster Response to the COVID-19 Pandemic for Patients with Kidney Disease in New York City. , 2020, Journal of the American Society of Nephrology : JASN.

[2]  E. Lewis,et al.  Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes , 2019, Arthritis & rheumatology.

[3]  R. Rennenberg,et al.  Biological Variation of Creatinine, Cystatin C, and eGFR over 24 Hours. , 2018, Clinical chemistry.

[4]  Mustafa Serteser,et al.  The EuBIVAS Project: Within- and Between-Subject Biological Variation Data for Serum Creatinine Using Enzymatic and Alkaline Picrate Methods and Implications for Monitoring. , 2017, Clinical chemistry.

[5]  B. Rovin,et al.  Update on Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[6]  Etienne Cavalier,et al.  Serum Creatinine: Not So Simple! , 2017, Nephron.

[7]  A. Vijayan,et al.  Prolonged Intermittent Renal Replacement Therapy. , 2016, Advances in chronic kidney disease.

[8]  N Fealy,et al.  Prolonged intermittent renal replacement therapy in the intensive care unit. , 2002, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[9]  C Ricós,et al.  Current databases on biological variation: pros, cons and progress. , 1999, Scandinavian journal of clinical and laboratory investigation.